Current investments

Receive information about current investment opportunities

Sign in or create an account to receive information about current share issues.

Sign in/Create account

Completed investments

Capitainer

Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.

Read more
Image showing a nanomolecular structure.

Synartro: 2

Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.

Read more
An enlarged image of nerve cells with nerve fibers, so-called axons.

PharmNovo

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

Read more
The Sciety syndicate invests in Synartro Synartro is developing a novel therapy for knee osteoarthritis.

Synartro: 1

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Read more
Show more

Exits

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more
Sciety_Cartana_NeuroKits

Cartana

Cartana’s patent-applied research tool revolutionizes the possibility of analyzing tissue samples, providing pharmaceutical companies with important information in their quest for new treatments.

Read more

Inhalation Sciences

Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.

Read more

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Read more
Show more